Skip to main content
SpringerLink
Log in

Health care utilization among adenosine-sensitive supraventricular tachycardia patients presenting to the emergency department

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Purpose

Although adenosine-sensitive supraventricular tachycardia (SVT) is generally curable, it remains an important cause of healthcare utilization. We sought to determine predictors of health care utilization among SVT patients presenting to the emergency department (ED).

Methods

We studied consecutive patients evaluated in an urban, academic ED for adenosine-sensitive SVT. The primary study outcomes were (1) ambulance transportation to the index ED visit, (2) hospital admission from the index ED encounter, and (3) recurrent SVT-associated ED encounters.

Results

Among 100 patients with adenosine-sensitive SVT, 35 were transported to the ED by ambulance. Prior electrophysiologist evaluation was associated with a significant 87% reduced odds of ambulance utilization (OR 0.13, 95% CI 0.03–0.67, p = 0.015). A total of 62 patients were subsequently admitted to the hospital. All patients with coronary artery disease, diabetes, syncope, and wide complex SVT were admitted. Similarly, individuals with an elevated troponin had a significantly greater odds of hospital admission (OR 16.8, 95% CI 1.9–148.4, p = 0.011). After the index ED visit, 60 patients were seen by an electrophysiologist, and 47 underwent catheter ablation. Individuals treated with catheter ablation had a significant 75% reduction in the risk of a recurrent ED visit for SVT (HR 0.25, 95% CI 0.10–0.62, p = 0.003).

Conclusions

Readily modifiable clinical factors, including a previous visit to an electrophysiologist and treatment with catheter ablation, are associated with reduced health care utilization among patients presenting to the ED with SVT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Orejarena LA, Vidaillet H, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998;31(1):150–7.

    Article  CAS  PubMed  Google Scholar 

  2. Murman DH, McDonald AJ, Pelletier AJ, Camargo CA. U.S. emergency department visits for supraventricular tachycardia, 1993–2003. Acad Emerg Med Off J Soc Acad Emerg Med. 2007;14(6):578–81.

    Google Scholar 

  3. Page, R. L., Joglar, J. A., Caldwell, M. A., Calkins, H., Conti, J. B., Deal, B. J., et al. (2015). 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology.

  4. Delacrétaz E. Clinical practice. Supraventricular tachycardia. N Engl J Med. 2006;354(10):1039–51. doi:10.1056/NEJMcp051145.

    Article  PubMed  Google Scholar 

  5. Rankin AC, Brooks R, Ruskin JN, McGovern BA. Adenosine and the treatment of supraventricular tachycardia. Am J Med. 1992;92(6):655–64.

    Article  CAS  PubMed  Google Scholar 

  6. Alboni P, Tomasi C, Menozzi C, Bottoni N, Paparella N, Fucà G, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 2001;37(2):548–53.

    Article  CAS  PubMed  Google Scholar 

  7. Tendera M, Wnuk-Wojnar AM, Kulakowski P, Malolepszy J, Kozlowski JW, Krzeminska-Pakula M, et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am Heart J. 2001;142(1):93–8.

    Article  CAS  PubMed  Google Scholar 

  8. Mauritson DR, Winniford MD, Walker WS, Rude RE, Cary JR, Hillis LD. Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, double-blind randomized trial. Ann Intern Med. 1982;96(4):409–12.

    Article  CAS  PubMed  Google Scholar 

  9. Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol. 1984;54(8):1138–9.

    Article  CAS  PubMed  Google Scholar 

  10. Anderson JL, Platt ML, Guarnieri T, Fox TL, Maser MJ, Pritchett EL. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group. Am J Cardiol. 1994;74(6):578–84.

    Article  CAS  PubMed  Google Scholar 

  11. Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991;114(7):539–44.

    Article  CAS  PubMed  Google Scholar 

  12. Wanless RS, Anderson K, Joy M, Joseph SP. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997;133(4):441–6.

    Article  CAS  PubMed  Google Scholar 

  13. Henthorn RW, Waldo AL, Anderson JL, Gilbert EM, Alpert BL, Bhandari AK, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation. 1991;83(1):119–25.

    Article  CAS  PubMed  Google Scholar 

  14. Cockrell JL, Scheinman MM, Titus C, Helmy I, Langberg JJ, Lee MA, et al. Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia. Ann Intern Med. 1991;114(3):189–94.

    Article  CAS  PubMed  Google Scholar 

  15. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. (1995). Circulation, 92(9), 2550–2557.

  16. Benditt DG, Dunnigan A, Buetikofer J, Milstein S. Flecainide acetate for long-term prevention of paroxysmal supraventricular tachyarrhythmias. Circulation. 1991;83(1):345–9.

    Article  CAS  PubMed  Google Scholar 

  17. Bathina MN, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto FM. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. Am J Cardiol. 1998;82(5):589–93.

    Article  CAS  PubMed  Google Scholar 

  18. Goldberg AS, Bathina MN, Mickelsen S, Nawman R, West G, Kusumoto FM. Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol. 2002;89(9):1120–3.

    Article  PubMed  Google Scholar 

  19. Calkins H, Yong P, Miller JM, Olshansky B, Carlson M, Saul JP, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation. 1999;99(2):262–70.

    Article  CAS  PubMed  Google Scholar 

  20. Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation. 1996;94(7):1585–91.

    Article  CAS  PubMed  Google Scholar 

  21. Lau CP, Tai YT, Lee PW. The effects of radiofrequency ablation versus medical therapy on the quality-of-life and exercise capacity in patients with accessory pathway-mediated supraventricular tachycardia: a treatment comparison study. Pacing and clinical electrophysiology : PACE. 1995;18(3 Pt 1):424–32.

    Article  CAS  PubMed  Google Scholar 

  22. Farkowski MM, Pytkowski M, Maciag A, Golicki D, Kowalik I, Czech M, et al. Patient’s age rather than severity of the arrhythmia influences the cost of medical treatment of atrioventricular nodal or atrioventricular reciprocating tachycardia. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 2016;47(2):197–202.

    Article  Google Scholar 

  23. Bukkapatnam RN, Robinson M, Turnipseed S, Tancredi D, Amsterdam E, Srivatsa UN. Relationship of myocardial ischemia and injury to coronary artery disease in patients with supraventricular tachycardia. Am J Cardiol. 2010;106(3):374–7.

    Article  PubMed  Google Scholar 

  24. Carlberg DJ, Tsuchitani S, Barlotta KS, Brady WJ. Serum troponin testing in patients with paroxysmal supraventricular tachycardia: outcome after ED care. Am J Emerg Med. 2011;29(5):545–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA

    Thomas A. Dewland

  2. Department of Medicine, Division of Cardiology, Electrophysiology Section, University of California San Francisco, 500 Parnassus Ave, M1180B, San Francisco, CA, 94143-0124, USA

    Adam Oesterle & Gregory M. Marcus

  3. Department of Emergency Medicine, University of California San Francisco, San Francisco, CA, USA

    John Stein

Authors
  1. Thomas A. Dewland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adam Oesterle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gregory M. Marcus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory M. Marcus.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dewland, T.A., Oesterle, A., Stein, J. et al. Health care utilization among adenosine-sensitive supraventricular tachycardia patients presenting to the emergency department. J Interv Card Electrophysiol 49, 103–109 (2017). https://doi.org/10.1007/s10840-017-0259-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-017-0259-1

Keywords

Search

Navigation